Ireland-based medical device company Medtronic has secured the CE mark for its SureTune2 software, which aids physicians programme patient’s deep brain stimulation (DBS) therapy.
DBS therapy triggers mild electrical stimulation to target areas in the brain which modulate specific symptom control.
Leads are inserted into the brain which stimulates the brain targets. They are connected to an implantable neurostimulator through extensions running under the skin.
The physician can set and regulate the stimulation settings by means of an external programmer.
The SureTune2 software is designed to suit Medtronic’s DBS therapy and other DBS therapy delivery systems as it generates patient-specific information in one comprehensive view including anatomy, physiology, and calculated stimulation field in a visual form.
Physicians can classify the segment structures either using a greyscale threshold in the target area or by outlining shapes of interest from a patient image.
Medtronic restorative therapies group brain modulation business vice-president and general manager Lothar Krinke said: "Medtronic is committed to providing advanced technology to the multidisciplinary teams who are helping DBS patients, and I am convinced that SureTune will provide them with easy-to-use tools to aid in optimising therapy outcomes.
"SureTune is a key aspect of Medtronic's commitment to providing integrated solutions for improving accuracy and confidence from surgery to post-operative DBS patient management."
According to the University Clinic of Würzburg chairman and professor of neurology Jens Volkmann, the SureTune software makes the trial and process associated with the DBS therapy easier by aiding in the identification of the best contacts which saves time as well.